Abstract
Hepatocellular carcinoma (HCC) is a critical global health issue and the third most common cause of cancer-related deaths worldwide. The majority of patients who present HCC are already at an advanced stage and their tumors are unresectable. Sorafenib is a multi-kinase inhibitor of the vascular endothelial growth factor pathway and was recently introduced as a therapy for advanced HCC. Furthermore, studies have shown that oral sorafenib has beneficial effects on survival. However, many patients experience diverse side effects, and some of these are severe. Liver abscess development has not been previously documented to be associated with sorafenib administration in HCC. Here, we report the case of a HCC patient that developed a liver abscess while being treated with sorafenib.
MeSH terms
-
Anti-Bacterial Agents / therapeutic use
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Hepatocellular / diagnostic imaging
-
Carcinoma, Hepatocellular / drug therapy*
-
Clostridium / isolation & purification
-
Clostridium Infections / drug therapy
-
Clostridium Infections / microbiology
-
Humans
-
Liver Abscess / etiology
-
Liver Abscess / microbiology*
-
Liver Neoplasms / diagnostic imaging
-
Liver Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Niacinamide / adverse effects
-
Niacinamide / analogs & derivatives*
-
Niacinamide / therapeutic use
-
Phenylurea Compounds / adverse effects
-
Phenylurea Compounds / therapeutic use*
-
Sorafenib
-
Tomography, X-Ray Computed
Substances
-
Anti-Bacterial Agents
-
Antineoplastic Agents
-
Phenylurea Compounds
-
Niacinamide
-
Sorafenib